Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Verstovsek on JAK Inhibition in Polycythemia Vera

November 26th 2018

Srdan Verstovsek, MD, PhD, director of the Hanns A. Pielenz Clinical Research Center for Myeloproliferative Neoplasms at The University of Texas MD Anderson Cancer Center, discusses JAK inhibition in the treatment of polycythemia vera.

Roswell Park Transplant Specialists Explore New Strategies for Tackling GVHD

November 24th 2018

Investigators at Roswell Park Comprehensive Cancer Center in Buffalo, New York, are working on a variety of novel approaches, including developing prophylactic drug regimens, studying methods of rejuvenating the recipient’s immune system, and analyzing genetic characteristics to improve donor selection.

FDA Grants Quizartinib Priority Review for FLT3-ITD+ AML

November 22nd 2018

The FDA has granted a priority review designation to a new drug application for quizartinib for the treatment of adult patients with relapsed/refractory FLT3-ITD–positive acute myeloid leukemia.

FDA Approves Glasdegib for Frontline AML

November 21st 2018

The FDA has approved glasdegib for use in combination with low-dose cytarabine for the treatment of patients with newly-diagnosed acute myeloid leukemia who are aged 75 years or older or who are ineligible for intensive chemotherapy.

FDA Approves Frontline Venetoclax in AML

November 21st 2018

The FDA has granted an accelerated approval to venetoclax for use in combination with azacitidine or decitabine or low-dose cytarabine for the treatment of adult patients with newly-diagnosed acute myeloid leukemia (AML) who are aged 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

Targeted Therapies Continue to Transform AML Treatment

November 21st 2018

Geoffrey Uy, MD, discusses the impact of targeted therapies on the treatment of patients with newly diagnosed acute myeloid leukemia.

Dr. Perl on Evolving Treatment in AML

November 19th 2018

Alexander E. Perl, MD, assistant professor of medicine, University of Pennsylvania, discusses the evolving treatment landscape in acute myeloid leukemia.

Dr. Deol on the FDA Approval of Eltrombopag in Severe Aplastic Anemia

November 17th 2018

Abhinav Deol, MD, associate professor, Karmanos Cancer Institute, discusses the expanded FDA approval of eltrombopag (Promacta) in combination with standard immunosuppressive therapy for the treatment of newly diagnosed adult and pediatric patients 2 years and older with severe aplastic anemia.

Dr. Green on Treatment Regimens for Patients With Multiple Myeloma in Early Relapse

November 13th 2018

Michael Green, MD, Northern California Oncologist, discusses his preferred treatment regimens for patients with multiple myeloma in early relapse.

Hispanics Are at Highest Risk of Neurotoxicity From Chemotherapy for ALL

November 12th 2018

Ethnic differences in the prevalence of neurotoxicity from methotrexate therapy may help explain why minority patients, specifically Hispanics, experience disparities in treatment outcomes for pediatric acute lymphoblastic leukemia.

Expert Breaks Down Data With TKI Discontinuation in CML

November 10th 2018

Meagan A. Jacoby, MD, PhD, discusses treatment-free remissions in patients with chronic-phase chronic myeloid leukemia.

Dr. Scherber Discusses Ruxolitinib Failure in Myelofibrosis

November 10th 2018

Robyn M. Scherber, MD, MPH, physician, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses ruxolitinib (Jakafi) failure in patients with myelofibrosis (MF).

Dr. Vij on Maintenance and Consolidation in Newly Diagnosed Multiple Myeloma

November 9th 2018

Ravi Vij, MD, MBA, professor of medicine, Division of Oncology, Section of Bone Marrow Transplant, Washington University School of Medicine, Siteman Cancer Center, discusses the use of maintenance and consolidation in multiple myeloma.

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

November 8th 2018

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

Prodrugs in Oncology: Teaching Old and New Drugs More Tricks

November 7th 2018

As researchers gain a better understanding of the unique aspects of individual tumor types and their surrounding microenvironment, the design of novel therapies categorized as prodrugs is become increasingly sophisticated, and several novel constructs show particular promise.

Dr. Valent on Dose-Adjusted Carfilzomib in Myeloma

November 6th 2018

Jason Valent, MD, an oncologist at Cleveland Clinic, discusses the recent FDA approval of dose-adjusted carfilzomib in patients with myeloma.

Dr. Kahl on Considerations for Treatment Strategies in CLL

November 6th 2018

Brad Kahl, MD, professor in the Department of Medicine, Washington University School of Medicine, Siteman Cancer Center, discusses considerations for treatment strategies in patients with chronic lymphocytic leukemia.

Expert Explains Latest Developments in Multiple Myeloma

November 1st 2018

Jason Valent, MD, discusses the current and future landscape of relapsed/refractory multiple myeloma.

Daratumumab Plus Lenalidomide/Dexamethasone Improves PFS in Frontline Myeloma Trial

October 30th 2018

Adding daratumumab to lenalidomide and dexamethasone reduced the risk of disease progression or death by 45% compared with lenalidomide/dexamethasone alone in newly diagnosed patients with multiple myeloma who are not candidates for high-dose chemotherapy and autologous stem-cell transplant.

Dr. Fakhri on Daratumumab Plus VMP in Multiple Myeloma

October 30th 2018

Bita Fakhri, MD, MPH, a professor of medicine in the Division of Hematology/Oncology at the University of California, San Francisco Helen Diller Family Comprehensive Cancer Center, discusses the data behind the frontline approval of daratumumab (Darzalex) in combination with bortezomib (Velcade), melphalan, and prednisone (VMP) in multiple myeloma.